AstraZeneca said it is beginning Phase I/II clinical trials of its COVID-19 vaccine candidate in Japan, as reported in Yahoo!Finance.
The trials of the vaccine AZD1222 will be conducted at multiple facilities in the country and target 250 subjects.
The company is working with Daiichi Sankyo and JCR Pharma in Japan to make and distribute the vaccine.
To read more NewsPoints articles, click here.
About FirstWord Pharma | Upgrade Your FirstWord Pharma | Contact FirstWord Pharma | FirstWord Reports
Advertise with FirstWord Pharma | Industry Partner Showcase
All Contents Copyright © 2021 Doctor's Guide Publishing Limited. All Rights Reserved.
Terms of Use | Privacy Policy